Jin LiShenzhen Ellen-Sven Precision Medicine Institute, China
Title: A new strategy – prevention, early detection and early treatment of cancer
World Health Organization (WHO) estimated in 2014 that the number of new cancer patients would increase by about 70% worldwide in the next 25 years. We face the battle against cancer now. Cancer is a disease of abnormal proliferating cells. Gene mutations associated with cell growth regulation leads to uncontrolled proliferation and thus malignancy. A precise molecule, human thymidine kinase 1 (HTK1) –a key enzyme involved in the DNA synthesis during the cell cycle. HTK1 is present intracellular and in blood serum of malignancy, but almost undetectable in healthly people. Many serum biomarkers have been tested during the last decades but still few are suitable for pre-cancer and early tumour detection. We developed successfully chicken anti-HTK1 IgY-antibody with high sensitivity and specificity for detection of serum thymidine kinase 1 concentration (STK1p). A series of academic reports demonstrated that elevated STK1p indicate 3-5 higher risk to develop cancer compared to the low-STK1p in health screening (n=160,086). Meta-analysis of five types of tumours (colorectal, lung, liver, breast and gastrointestinal) indicated that the STK1p value increases significantly?P?0.0001) in the following manner: tumour-free (n=7,551<benign/pre-cancerous (n=4,224)<carcinoma (n=8329, clinical stage T1-3). Elevated STK1p of post-treatment was associated with poor survival in stage I-II of carcinomas. So far, STK1p is one of few biomarkers that can be used for risk assessment of pre-cancer and increase the chance to cure. We suggested that in combination with appropriate imaging, STK1p could be an important tool in precise medicine for prognosis of pre- and early malignant cancer, both in health screening and oncology clinics. We describe a way to fulfil the recommendations of WHO of preventing development of cancer and early detection of pre-cancer/cancer to increase patient chance to be cured. This also reduces patient costs, which is an integral factor in today’s cancer treatments.
Jin Li, Department of Medicine, Shenzhen Ellen-Sven Precision Medicine Institute, Shenzhen, 518110, China. He is a clinical doctor in the field of Ophthalmology since 1995. He started to work at Tongji Hospital of Tongji Medical University, continue at Tongji Medical College, Huazhong University of Science and Technology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, all in Wuhan, China, and then, moved to People’s Hospital, Second Medical College of Jinan University, Shenzhen, China. In 2004-2010 he studied a scientific course in Dusiburg-Essen University, Germany and got PhD degree. He is a Professor Since 2017 he is director of Shenzhen Ellen & Sven Precision Medical Research Institute. Dr Li has published more than 10 scientific papers.